Influence of intrahepatic cholestasis of pregnancy on adverse pregnancy outcomes of HBV-infected pregnant women

Xiali XIONG; Yunxia ZHU; Hong WEI; Zhiqiang ZHAO; Jun MENG; Huaibin ZOU; Zhongping DUAN

doi:10.3969/j.issn.1001-5256.2022.08.009

Volume 38 Issue 8

Aug. 2022

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(8): 1763-1767

PDF( 1899 KB)

Influence of intrahepatic cholestasis of pregnancy on adverse pregnancy outcomes of HBV-infected pregnant women

DOI: 10.3969/j.issn.1001-5256.2022.08.009

a.
Department of Obstetrics, Beijing YouAn Hospital, Capital Medical University, Beijing 100069, China
b.
Intractable Hepatic Diseases and Artificial Liver Treatment & Training Center, Beijing YouAn Hospital, Capital Medical University, Beijing 100069, China

Research funding:

National Science and Technology Key Project on "Major Infectious Diseases such as HIV/AIDS, Viral Hepatitis Prevention and Treatment" (2017ZX10201201-001-001);

National Science and Technology Key Project on "Major Infectious Diseases such as HIV/AIDS, Viral Hepatitis Prevention and Treatment" (2017ZX10201201-002-002);

National Science and Technology Key Project on "Major Infectious Diseases such as HIV/AIDS, Viral Hepatitis Prevention and Treatment" (2017ZX10201201-002-009);

Beijing Municipal Hospital Scientific Research and Cultivation Program (PX2020067)

More Information

Corresponding author: DUAN Zhongping, duan@ccmu.edu.cn(ORCID: 0000-0002-5927-5979)
Received Date: 2022-05-13
Accepted Date: 2022-06-16
Published Date: 2022-08-20

Abstract

Abstract

Objective To investigate the influence of intrahepatic cholestasis of pregnancy (ICP) on adverse pregnancy outcomes of hepatitis B virus (HBV)-infected pregnant women. Methods A retrospective analysis was performed for 232 pregnant women with chronic HBV infection who were admitted to Beijing YouAn Hospital, Capital Medical University, from March 2018 to March 2021. According to the presence or absence of ICP, the patients were divided into HBV infection group with 100 patients and HBV+ICP group with 132 patients; according to the severity of ICP, the patients in the HBV+ICP group were further divided into HBV+mild ICP group with 86 patients and HBV+severe ICP group with 46 patients. The above groups were compared in terms of the incidence rates of maternal complications during pregnancy, such as premature delivery, premature rupture of membranes, gestational diabetes mellitus, hypertensive disorder complicating pregnancy, and postpartum hemorrhage (PPH), as well as the adverse outcomes of fetus/neonate, such as intrauterine fetal death, neonatal asphyxia, amniotic fluid pollution degree Ⅲ(AFⅢ), neonatal respiratory distress syndrome, small-for-gestational-age (SGA), admission to the neonatal intensive care unit, pneumonia, and mother-to-child transmission (MTCT) of HBV. A one-way analysis of variance was used for comparison between multiple groups; the chi-square test, the chi-square test with continuity correction or the Fisher's exact test was used for comparison of categorical data between multiple groups. Results Compared with the HBV infection group in terms of maternal complications in late pregnancy, the HBV+ICP group had significantly higher incidence rates of premature delivery and PPH (χ²=4.169 and 5.448, P=0.041 and 0.020), and in terms of the adverse outcomes of neonates, the HBV+ICP group had significantly higher incidence rates of neonatal asphyxia, AFⅢ, and SGA than the HBV infection group (χ²=5.448, 16.567, and 11.053, P=0.020, P < 0.001, and P=0.002). In terms of the adverse outcomes of neonates, the HBV+severe ICP group had significantly higher incidence rates of AFⅢ and SGA than the HBV+mild ICP group (χ²=4.200 and 4.511, P=0.040 and 0.034). Conclusion Compared with the pregnant women with HBV infection alone, the pregnant women with HBV infection and ICP have significantly higher incidence rates of adverse pregnancy outcomes in mothers and neonates, and the incidence rate of adverse outcomes in neonates increases with the increase in the severity of ICP. However, ICP has no influence on HBV MTCT.
- Hepatitis B Virus,
- Cholestasis, Intrahepatic,
- Pregnancy

FullText(HTML)

References(23)

References

[1]	Obstetrics Subgroup, Chinese Society of Obstetrics and Gynecology, Chinese Medical Association. Guidelines for the management of intrahepatic cholestasis of pregnancy (2015)[J]. J Clin Hepatol, 2015, 31(10): 1575-1578. DOI: 10.3969/j.issn.1001-5256.2015.10.003. 中华医学会妇产科学分会产科学组. 妊娠期肝内胆汁淤积症诊疗指南(2015)[J]. 临床肝胆病杂志, 2015, 31(10): 1575-1578. DOI: 10.3969/j.issn.1001-5256.2015.10.003.
[2]	XIN X, WANG Y, CHENG J, et al. Seroepidemiological survey of hepatitis B virus infection among 764, 460 women of childbearing age in rural China: A cross-sectional study[J]. J Clin Virol, 2016, 81: 47-52. DOI: 10.1016/j.jcv.2016.05.014.
[3]	KUNTZ M, KUNTZ HD. Hepatology textbook and atlas[M]. Berlin, Heidelberg: Springer, 2008.
[4]	CHEN YC, ZHANG YM, ZHANG HS, et al. Effects of viral load of HBV-infected pregnant women on the humoral immune status and neonatal HBV infection rate[J]. Int J Virol, 2022, 29(1): 49-53. DOI: 10.3760/cma.j.issn.1673-4092.2022.01.010. 陈月婵, 张艳敏, 张红升, 等. HBV感染孕妇病毒载量对体液免疫状态及新生儿HBV感染率的影响[J]. 国际病毒学杂志, 2022, 29(1): 49-53. DOI: 10.3760/cma.j.issn.1673-4092.2022.01.010.
[5]	CHEN Y, TIAN Z. HBV-induced immune imbalance in the development of HCC[J]. Front Immunol, 2019, 10: 2048. DOI: 10.3389/fimmu.2019.02048.
[6]	Chinese Society of Infectious Diseases, Chinese Medical Association, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007. 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
[7]	SHEN JC, LENG XJ, ZHANG Y, et al. Interpretation of managing HBV in pregnancy. Prevention, prophylaxis, treatment and follow-up[J]. J Clin Hepatol, 2016, 32(6): 1060-1068. DOI: 10.3969/j.issn.1001-5256.2016.06.008. 申姣春, 冷雪君, 张莹, 等. 《妊娠期HBV的阻断、预防、治疗和随访管理》解读[J]. 临床肝胆病杂志, 2016, 32(6): 1060-1068. DOI: 10.3969/j.issn.1001-5256.2016.06.008.
[8]	PIECHOTA J, JELSKI W. Intrahepatic cholestasis in pregnancy: Review of the literature[J]. J Clin Med, 2020, 9(5): 1361. DOI: 10.3390/jcm9051361.
[9]	LIU Y, MA C, JIA H, et al. Knowledge, attitudes, and practices regarding hepatitis B vaccination among hospital-based doctors and nurses in China: Results of a multi-site survey[J]. Vaccine, 2018, 36(17): 2307-2313. DOI: 10.1016/j.vaccine.2018.03.018.
[10]	YULE CS, HOLCOMB DS, KRAUS AC, et al. Cholestasis: A prospective study of perinatal outcomes and time to symptom improvement[J]. Am J Perinatol, 2021, 38(5): 414-420. DOI: 10.1055/s-0040-1717076.
[11]	GERMAIN AM, KATO S, CARVAJAL JA, et al. Bile acids increase response and expression of human myometrial oxytocin receptor[J]. Am J Obstet Gynecol, 2003, 189(2): 577-582. DOI: 10.1067/s0002-9378(03)00545-3.
[12]	KONDRACKIENE J, KUPCINSKAS L. Intrahepatic cholestasis of pregnancy-current achievements and unsolved problems[J]. World J Gastroenterol, 2008, 14(38): 5781-5788. DOI: 10.3748/wjg.14.5781.
[13]	ARTHUIS C, DIGUISTO C, LORPHELIN H, et al. Perinatal outcomes of intrahepatic cholestasis during pregnancy: An 8-year case-control study[J]. PLoS One, 2020, 15(2): e0228213. DOI: 10.1371/journal.pone.0228213.
[14]	WU K, WANG H, LI S, et al. Maternal hepatitis B infection status and adverse pregnancy outcomes: a retrospective cohort analysis[J]. Arch Gynecol Obstet, 2020, 302(3): 595-602. DOI: 10.1007/s00404-020-05630-2.
[15]	ROY A, PREMKUMAR M, MISHRA S, et al. Role of ursodeoxycholic acid on maternal serum bile acids and perinatal outcomes in intrahepatic cholestasis of pregnancy[J]. Eur J Gastroenterol Hepatol, 2021, 33(4): 571-576. DOI: 10.1097/MEG.0000000000001954.
[16]	ZHANG C, WEI H, ZHU YX. Adverse pregnancy outcomes and mother-to-child transmission in patients with hepatitis B virus infection and intrahepatic cholestasis of pregnancy[J]. Ginekol Pol, 2021. DOI: 10.5603/GP.a2021.0110. [Online ahead of print]
[17]	ABU-HAYYEH S, PAPACLEOVOULOU G, LÖVGREN-SANDBLOM A, et al. Intrahepatic cholestasis of pregnancy levels of sulfated progesterone metabolites inhibit farnesoid X receptor resulting in a cholestatic phenotype[J]. Hepatology, 2013, 57(2): 716-726. DOI: 10.1002/hep.26055.
[18]	BATSRY L, ZLOTO K, KALTER A, et al. Perinatal outcomes of intrahepatic cholestasis of pregnancy in twin versus singleton pregnancies: is plurality associated with adverse outcomes?[J]. Arch Gynecol Obstet, 2019, 300(4): 881-887. DOI: 10.1007/s00404-019-05247-0.
[19]	LEE RH, KWOK KM, INGLES S, et al. Pregnancy outcomes during an era of aggressive management for intrahepatic cholestasis of pregnancy[J]. Am J Perinatol, 2008, 25(6): 341-345. DOI: 10.1055/s-2008-1078756.
[20]	ROOK M, VARGAS J, CAUGHEY A, et al. Fetal outcomes in pregnancies complicated by intrahepatic cholestasis of pregnancy in a Northern California cohort[J]. PLoS One, 2012, 7(3): e28343. DOI: 10.1371/journal.pone.0028343.
[21]	KREMER AE, WOLF K, STÄNDER S. Intrahepatic cholestasis of pregnancy: Rare but important[J]. Hautarzt, 2017, 68(2): 95-102. DOI: 10.1007/s00105-016-3923-y.
[22]	ZECCA E, de LUCA D, BARONI S, et al. Bile acid-induced lung injury in newborn infants: a bronchoalveolar lavage fluid study[J]. Pediatrics, 2008, 121(1): e146-e149. DOI: 10.1542/peds.2007-1220.
[23]	FUNK AL, LU Y, YOSHIDA K, et al. Efficacy and safety of antiviral prophylaxis during pregnancy to prevent mother-to-child transmission of hepatitis B virus: a systematic review and meta-analysis[J]. Lancet Infect Dis, 2021, 21(1): 70-84. DOI: 10.1016/S1473-3099(20)30586-7.

Relative Articles

[1]	Zhang Dan, Zhou Bo, Deng Yi, Wen Yu, Lu: JunYan, Wang JinXiang, Geng ZuoTao, Luo SuFeng, Ying YunYan, Wen DaiYan, Shi ChunJing, Pu GuangYu, Jiang Xin, Ma LanQing. Effect of fenofibrate on the diversity of intestinal flora in a mouse model of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(4): 829-834. doi: 10.3969/j.issn.1001-5256.2020.04.024
[2]	Chen Hao, Hao JianHeng, Li ZhenCheng, Xu HuiChao, Gao Yan, Miao YuChuan, Hao HuiQin, Liu Yang. Screening for differentially expressed genes in mice with autoimmune hepatitis and effect of saikosaponin-d on the expression of several differentially expressed genes[J]. Journal of Clinical Hepatology, 2020, 36(4): 840-846. doi: 10.3969/j.issn.1001-5256.2020.04.026
[3]	Tan Peng, Chen Hao, Wang AnKang, Qian BaoLin, Huang ZhiWei, Shi Hao, Gao Lin, Fu WenGuang. Effect of triptolide on fibrosis in a mouse model of cerulean-induced chronic pancreatitis[J]. Journal of Clinical Hepatology, 2020, 36(3): 641-645. doi: 10.3969/j.issn.1001-5256.2020.03.034
[4]	Du YiChao, Zhang Hao, Zhong FuRui, Cheng HuanLi, Lai Li, Qian BaoLin, Tan Peng, Xia XianMing, Fu WenGuang. Protective effect of pinocembrin in a mouse model of liver injury induced by acetaminophen[J]. Journal of Clinical Hepatology, 2020, 36(3): 608-611. doi: 10.3969/j.issn.1001-5256.2020.03.027
[5]	Yang ShuJuan, Guo YaLing, Fu Shan, He YingLi, Zhao YingRen, Tian Zhen. Role of the specific inhibitor of 5-lipoxygenase-activating protein MK886 in inhibiting alcoholic liver disease in mice[J]. Journal of Clinical Hepatology, 2019, 35(8): 1791-1796. doi: 10.3969/j.issn.1001-5256.2019.08.028
[6]	Zhao XiaoFang, Tang YouMing, Xu XinJie, Tang YanFang, Liu XuDong, Lu: Ping, Zhao ZhuangZhi. Effect on JNK1 gene silencing on the expression of high-molecular-weight adiponectin in mice with nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2019, 35(10): 2257-2260. doi: 10.3969/j.issn.1001-5256.2019.10.025
[7]	Wang KaiXia, Zheng Chao, Zhang JingHao, Zhu XiaoJun, Wang Xuan, Kong XiaoNi, Gao YueQiu, Sun XueHua. Clinical effect of Qingre Jiedu Liangxue prescription in treatment of mice with acute-on-chronic liver failure and related mechanism[J]. Journal of Clinical Hepatology, 2019, 35(12): 2765-2771. doi: 10.3969/j.issn.1001-5256.2019.12.025
[8]	Bi YanZhen, Zhang QiuSheng, Fan Zeng, Yang YongHong, Zhang XiaoBei, Wang QuanQuan, Wang QuanYi, Wang YiBo, Duan ZhongPing, Chen Yu, Shu ZhenFeng, Si ChuanPing, Hong Feng. Effect of human liver-derived stem cells in prevention and treatment of alcoholic fatty liver disease in mice[J]. Journal of Clinical Hepatology, 2019, 35(3): 592-595. doi: 10.3969/j.issn.1001-5256.2019.03.027
[9]	Wang XiaoXiao, Zhao Jie, Li XiaoHe, Rao HuiYing, Wei Lai, Liu Feng. Value of second harmonic generation/two-photon excitation fluorescence in quantitative evaluation of liver fibrosis in mice with nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2019, 35(8): 1786-1790. doi: 10.3969/j.issn.1001-5256.2019.08.027
[10]	Yang DaYin, Du YiChao, Tan Peng, Chen Hao, Qian BaoLin, Wang AnKang, Huang ShiYao, Fu WenGuang, Xia XianMing. Effect of Hic-5 gene knockout on NF-κB/p65 expression and CCl4-induced liver fibrosis degree in mice[J]. Journal of Clinical Hepatology, 2019, 35(11): 2483-2488. doi: 10.3969/j.issn.1001-5256.2019.11.019
[11]	Pan Jing, Pan WenTing, Wu LiHui. Expression and significance of Th22 cells and its functional factor interleukin-22 in mice with autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2018, 34(8): 1745-1749. doi: 10.3969/j.issn.1001-5256.2018.08.030
[12]	Shi HongBo, Shi HongLin, Zhang XiangYing, Chen DeXi, Duan ZhongPing, Ren Feng. Protective effect of autophagy in mice with acute liver injury induced by D- galactosamine / lipopolysaccharide and related mechanisms[J]. Journal of Clinical Hepatology, 2017, 33(2): 329-333. doi: 10.3969/j.issn.1001-5256.2017.02.027
[13]	Mai JingYin, Chen TianYang, Cheng Yang. Changes in microRNA expression profile in the liver of mice with nonalcoholic fatty liver disease induced by high-fat diet[J]. Journal of Clinical Hepatology, 2017, 33(12): 2372-2375. doi: 10.3969/j.issn.1001-5256.2017.12.023
[14]	Chen Jing, Liu XiaoYan, Yang HaoZhen, Huang Kun, Hu JinHua, Xin ShaoJie. Study on p-p38 expression and its significance in liver tissues of mice with acute liver failure and patients with HBV-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2015, 31(4): 556-559. doi: 10.3969/j.issn.1001-5256.2015.04.019
[15]	Yan XiaoMing, Zhang LiTing, Luo JingYi, Xiao Ping. Therapeutic effect of estradiol-pretreated human bone marrow mesenchymal stem cells on liver cirrhosis in mice[J]. Journal of Clinical Hepatology, 2015, 31(3): 424-430. doi: 10.3969/j.issn.1001-5256.2015.03.026
[16]	Peng Yuan, Tao YanYan, Huang Kai, Zhao Qiang, Liu ChengHai. Regulatory effect of poly I∶C on intrahepatic natural killer cells in mouse model of liver injury induced by carbon tetrachloride[J]. Journal of Clinical Hepatology, 2015, 31(12): 2077-2083. doi: 10.3969/j.issn.1001-5256.2015.12.022
[17]	Huang HaiYan, Xin YongNing, Jiang Man, Jin WenWen, Jiang XiangJun, Xuan ShiYing. Research advances in animal models of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2014, 30(9): 948-953. doi: 10.3969/j.issn.1001-5256.2014.09.028
[18]	Ye LiHong, Wang ChongKui, Yang Li, Gao HuiXia, Zhao ZhaoXia, Hou JunLiang, Dai ErHei. Effects of Ruangan Huajian granule on hepatic expression of α-SMA, TGFβ1, and COL-Ⅰ in C57 mice with experimental hepatic fibrosis [J]. Journal of Clinical Hepatology, 2012, 28(9): 685-688.
[19]	Lou GuoHua, Liu YanNing, Yin ChunBen, Chen Feng, Jia ZhanSheng, Chen Zhi. Preliminary study of HCV mouse model induced by infectious HCV 2a plasmid[J]. Journal of Clinical Hepatology, 2011, 27(1): 72-75.
[20]	Ye LiHong, Wang ChongKui, Tian YueYang, Xu Yi, Zheng HaoJie, Shao ShiXiang, Dai ErHei. Effect of Ruangan Huajian granule on hepatic expression of PDGF - B in C57 mice with experimental hepatic fibrosis[J]. Journal of Clinical Hepatology, 2011, 27(10): 1047-1050.

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Tables(3)

Get Citation

PDF

XML

Article Metrics

Article views (629) PDF downloads(69)

Influence of intrahepatic cholestasis of pregnancy on adverse pregnancy outcomes of HBV-infected pregnant women

DOI: 10.3969/j.issn.1001-5256.2022.08.009

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Influence of intrahepatic cholestasis of pregnancy on adverse pregnancy outcomes of HBV-infected pregnant women

DOI: 10.3969/j.issn.1001-5256.2022.08.009

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content